NASDAQ:VAXX Vaxxinity (VAXX) Stock Forecast, Price & News $1.99 +0.01 (+0.51%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$1.92▼$2.0450-Day Range$1.73▼$2.4252-Week Range$1.24▼$4.47Volume118,956 shsAverage Volume131,781 shsMarket Capitalization$251.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Vaxxinity (NASDAQ:VAXX) StockVaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.Read More Receive VAXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter. Email Address VAXX Stock News HeadlinesMay 14, 2023 | americanbankingnews.comVaxxinity (NASDAQ:VAXX) Stock Price Down 7%May 9, 2023 | finance.yahoo.comVaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate UpdateJune 9, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 3, 2023 | finance.yahoo.comVaxxinity, Inc.'s (NASDAQ:VAXX) biggest owners are private companies who got richer after stock soared 23% last weekApril 24, 2023 | finance.yahoo.comWeekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro RecapApril 1, 2023 | americanbankingnews.comFY2023 EPS Estimates for Vaxxinity, Inc. Cut by Jefferies Financial Group (NASDAQ:VAXX)March 29, 2023 | americanbankingnews.comAnalysts Offer Predictions for Vaxxinity, Inc.'s Q1 2023 Earnings (NASDAQ:VAXX)March 28, 2023 | finance.yahoo.comVaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in AprilJune 9, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.March 28, 2023 | americanbankingnews.comVaxxinity (NASDAQ:VAXX) Issues Quarterly Earnings ResultsMarch 27, 2023 | finance.yahoo.comVaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdatesMarch 21, 2023 | finance.yahoo.comVaxxinity Joins TransCelerate Research and Development ConsortiumMarch 20, 2023 | finance.yahoo.comVaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat HypercholesterolemiaMarch 2, 2023 | finance.yahoo.comVaxxinity to Present at Upcoming March Scientific and Medical ConferencesFebruary 24, 2023 | markets.businessinsider.comNektar Therapeutics (NKTR) was downgraded to a Sell Rating at JefferiesJanuary 19, 2023 | finance.yahoo.comWhy Shares of Vaxxinity Jumped This WeekJanuary 5, 2023 | finance.yahoo.comVaxxinity to Present at the 2023 J.P. Morgan Healthcare ConferenceDecember 31, 2022 | finance.yahoo.comEstimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX)December 2, 2022 | finance.yahoo.comVaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612November 10, 2022 | finance.yahoo.comVaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 3, 2022 | finance.yahoo.comVaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022November 1, 2022 | finance.yahoo.comVaxxinity to Present at Upcoming Investor Conferences in NovemberOctober 30, 2022 | finance.yahoo.comVaxxinity, Inc. (NASDAQ:VAXX) stock most popular amongst private companies who own 48%, while individual investors hold 21%October 24, 2022 | finance.yahoo.comVaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in AustraliaOctober 11, 2022 | uk.finance.yahoo.comVaxxinity, Inc. (VAXX)October 3, 2022 | dallasnews.comUNT Health Science Center gets $150 million for massive Alzheimer’s study - The Dallas Morning NewsSeptember 21, 2022 | finance.yahoo.comImmunis Welcomes Dr. Peter Diamandis to the Executive Advisory Board - Yahoo FinanceSee More Headlines VAXX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VAXX Company Calendar Last Earnings3/27/2023Today6/08/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VAXX CUSIPN/A CIK1851657 Webwww.vaxxinity.com Phone254-244-5739FaxN/AEmployees87Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,220,000.00 Net MarginsN/A Pretax Margin-603,670.63% Return on Equity-105.46% Return on Assets-66.73% Debt Debt-to-Equity Ratio0.28 Current Ratio2.77 Quick Ratio2.77 Sales & Book Value Annual Sales$70,000.00 Price / Sales3,597.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.49 per share Price / Book4.06Miscellaneous Outstanding Shares126,540,000Free Float51,793,000Market Cap$251.81 million OptionableNot Optionable Beta2.71 Key ExecutivesMr. Louis Garfield Reese IV (Age 41)Co-Founder & Exec. Chairman Comp: $83.28kMs. Mei Mei Hu J.D. (Age 40)CEO & Director Comp: $551.73kMr. Rene Paula Molina J.D. (Age 45)Sr. VP of Legal & Bus. Affairs, Gen. Counsel & Sec. Comp: $480.13kDr. Ulo Palm M.D. (Age 66)Ph.D., Chief Medical Officer Comp: $585kMr. Jason Pesile CPA (Age 50)M.B.A., Sr. VP of Fin. & Accounting Mr. Dwayne SoissonVP of OperationsMr. Jon HarrisonChief Gov. OfficerMr. Mark JoinnidesChief of StaffMs. Amy B. Fix M.B.A.M.S., R.A.C., Chief Regulatory OfficerDr. Jean-Cosme Dodart Ph.D.Sr. VP of ResearchMore ExecutivesKey CompetitorsRani TherapeuticsNASDAQ:RANICarisma TherapeuticsNASDAQ:CARMZura BioNASDAQ:ZURAAadi BioscienceNASDAQ:AADIFoghorn TherapeuticsNASDAQ:FHTXView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 28,433 shares on 5/16/2023Ownership: 0.300%State Street CorpBought 66,200 shares on 5/16/2023Ownership: 0.096%Squarepoint Ops LLCBought 51,941 shares on 5/16/2023Ownership: 0.041%Jane Street Group LLCBought 43,730 shares on 5/16/2023Ownership: 0.035%Balyasny Asset Management L.P.Bought 36,344 shares on 5/16/2023Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions VAXX Stock - Frequently Asked Questions How have VAXX shares performed in 2023? Vaxxinity's stock was trading at $1.40 on January 1st, 2023. Since then, VAXX shares have increased by 42.1% and is now trading at $1.99. View the best growth stocks for 2023 here. When is Vaxxinity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our VAXX earnings forecast. How were Vaxxinity's earnings last quarter? Vaxxinity, Inc. (NASDAQ:VAXX) posted its quarterly earnings data on Monday, March, 27th. The company reported ($0.16) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.16). What ETF holds Vaxxinity's stock ? ETFMG Treatments Testing and Advancements ETF holds 43,836 shares of VAXX stock, representing 0.52% of its portfolio. When did Vaxxinity IPO? (VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. What is Vaxxinity's stock symbol? Vaxxinity trades on the NASDAQ under the ticker symbol "VAXX." Who are Vaxxinity's major shareholders? Vaxxinity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.30%), Bank of America Corp DE (0.25%), Susquehanna International Group LLP (0.24%), State Street Corp (0.10%), HRT Financial LP (0.05%) and Squarepoint Ops LLC (0.04%). Insiders that own company stock include Lou Reese, Mei Mei Hu, Movers Lab Fund I Lp Prime and United Biomedical Inc. View institutional ownership trends. How do I buy shares of Vaxxinity? Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vaxxinity's stock price today? One share of VAXX stock can currently be purchased for approximately $1.99. How much money does Vaxxinity make? Vaxxinity (NASDAQ:VAXX) has a market capitalization of $251.81 million and generates $70,000.00 in revenue each year. The company earns $-75,220,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. How can I contact Vaxxinity? The official website for the company is www.vaxxinity.com. The company can be reached via phone at 254-244-5739 or via email at ir@vaxxinity.com. This page (NASDAQ:VAXX) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.